Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus

被引:21
作者
Hancock, GE [1 ]
Smith, JD [1 ]
Heers, KM [1 ]
机构
[1] Wyeth Lederle Vaccines, Dept Immunol Res, W Henrietta, NY 14586 USA
关键词
D O I
10.1086/315475
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Subunit vaccines formulated with purified fusion proteins from the A2 (PFP-2) or attenuated 248/404 (PFP-3) strains of respiratory syncytial virus (RSV) were evaluated, either alone or in combination with native attachment (G) protein, for their ability to augment serum neutralizing antibody titers in seropositive chimpanzees. The results suggested that combination vaccines enhanced serum neutralizing antibody titers against both laboratory strains and clinical isolates of RSV, When compared with PFP-2 alone, the resultant neutralizing antibody titers after vaccination with PFP-2+Ga protein were significantly elevated against 71% of A strains tested. In a confirmatory experiment, immunization with PFP-3+Ga+Gb proteins resulted in elevated serum neutralizing antibody titers against 86% of A and 50% of B strains tested versus injection with PFP-3 alone. The results suggest that subunit vaccines composed of both PFP and G proteins have more potential than PFP alone to augment neutralizing antibody titers in seropositive recipients.
引用
收藏
页码:1768 / 1771
页数:4
相关论文
共 15 条
[1]   NEUTRALIZATION OF RESPIRATORY SYNCYTIAL VIRUS BY INDIVIDUAL AND MIXTURES OF F-PROTEIN AND G-PROTEIN MONOCLONAL-ANTIBODIES [J].
ANDERSON, LJ ;
BINGHAM, P ;
HIERHOLZER, JC .
JOURNAL OF VIROLOGY, 1988, 62 (11) :4232-4238
[2]   Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates [J].
Crowe, JE ;
Bui, PT ;
Firestone, CY ;
Connors, M ;
Elkins, WR ;
Chanock, RM ;
Murphy, BR .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (04) :829-839
[3]   Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment [J].
Domachowske, JB ;
Rosenberg, HF .
CLINICAL MICROBIOLOGY REVIEWS, 1999, 12 (02) :298-+
[4]   Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP 2) in ambulatory adults over age 60 [J].
Falsey, AR ;
Walsh, EE .
VACCINE, 1996, 14 (13) :1214-1218
[5]   Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly [J].
Falsey, AR ;
Walsh, EE .
VACCINE, 1997, 15 (10) :1130-1132
[6]   Nucleotide sequence analysis of the respiratory syncytial virus subgroup a cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate [J].
Firestone, CY ;
Whitehead, SS ;
Collins, PL ;
Murphy, BR ;
Crowe, JE .
VIROLOGY, 1996, 225 (02) :419-422
[7]   Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia [J].
Groothuis, JR ;
King, SJ ;
Hogerman, DA ;
Paradiso, PR ;
Simoes, EAF .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (02) :467-469
[8]   Respiratory syncytial virus pneumonia among the elderly: An assessment of disease burden [J].
Han, LL ;
Alexander, JP ;
Anderson, LJ .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :25-30
[9]   The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12 [J].
Hancock, GE ;
Smith, JD ;
Heers, KM .
VIRAL IMMUNOLOGY, 2000, 13 (01) :57-72
[10]   Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus [J].
Hancock, GE ;
Speelman, DJ ;
Heers, K ;
Bortell, E ;
Smith, J ;
Cosco, C .
JOURNAL OF VIROLOGY, 1996, 70 (11) :7783-7791